TY - JOUR
T1 - Advances in sequencing technologies for amyotrophic lateral sclerosis research
AU - Udine, Evan
AU - Jain, Angita
AU - van Blitterswijk, Marka
N1 - Funding Information:
MVB is supported by the National Institute of Neurological Disorders and Stroke (NINDS; NS123052 and NS121125) and the Spastic Paraplegia Foundation, Inc., (SPF), and previously by the National Ataxia Foundation and the Muscular Dystrophy Association. EU and AJ are supported by the Mayo Clinic Graduate School of Biomedical Sciences. AJ is further supported by Clinical and Translational Science Awards Program Grant Number TL1 TR002380 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH).
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Amyotrophic lateral sclerosis (ALS) is caused by upper and lower motor neuron loss and has a fairly rapid disease progression, leading to fatality in an average of 2-5 years after symptom onset. Numerous genes have been implicated in this disease; however, many cases remain unexplained. Several technologies are being used to identify regions of interest and investigate candidate genes. Initial approaches to detect ALS genes include, among others, linkage analysis, Sanger sequencing, and genome-wide association studies. More recently, next-generation sequencing methods, such as whole-exome and whole-genome sequencing, have been introduced. While those methods have been particularly useful in discovering new ALS-linked genes, methodological advances are becoming increasingly important, especially given the complex genetics of ALS. Novel sequencing technologies, like long-read sequencing, are beginning to be used to uncover the contribution of repeat expansions and other types of structural variation, which may help explain missing heritability in ALS. In this review, we discuss how popular and/or upcoming methods are being used to discover ALS genes, highlighting emerging long-read sequencing platforms and their role in aiding our understanding of this challenging disease.
AB - Amyotrophic lateral sclerosis (ALS) is caused by upper and lower motor neuron loss and has a fairly rapid disease progression, leading to fatality in an average of 2-5 years after symptom onset. Numerous genes have been implicated in this disease; however, many cases remain unexplained. Several technologies are being used to identify regions of interest and investigate candidate genes. Initial approaches to detect ALS genes include, among others, linkage analysis, Sanger sequencing, and genome-wide association studies. More recently, next-generation sequencing methods, such as whole-exome and whole-genome sequencing, have been introduced. While those methods have been particularly useful in discovering new ALS-linked genes, methodological advances are becoming increasingly important, especially given the complex genetics of ALS. Novel sequencing technologies, like long-read sequencing, are beginning to be used to uncover the contribution of repeat expansions and other types of structural variation, which may help explain missing heritability in ALS. In this review, we discuss how popular and/or upcoming methods are being used to discover ALS genes, highlighting emerging long-read sequencing platforms and their role in aiding our understanding of this challenging disease.
KW - Amyotrophic lateral sclerosis
KW - DNA sequencing
KW - Long-read sequencing
KW - Multi-omics
KW - Nanopore sequencing
KW - SMRT sequencing
UR - http://www.scopus.com/inward/record.url?scp=85146195143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146195143&partnerID=8YFLogxK
U2 - 10.1186/s13024-022-00593-1
DO - 10.1186/s13024-022-00593-1
M3 - Review article
C2 - 36635726
AN - SCOPUS:85146195143
SN - 1750-1326
VL - 18
JO - Molecular Neurodegeneration
JF - Molecular Neurodegeneration
IS - 1
M1 - 4
ER -